Gateway Investment Advisers LLC boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 97.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,581 shares of the medical research company's stock after purchasing an additional 5,726 shares during the quarter. Gateway Investment Advisers LLC's holdings in Edwards Lifesciences were worth $857,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in EW. Dimensional Fund Advisors LP grew its stake in Edwards Lifesciences by 18.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company's stock worth $129,271,000 after purchasing an additional 219,486 shares in the last quarter. Edgestream Partners L.P. acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $438,000. Brighton Jones LLC increased its holdings in shares of Edwards Lifesciences by 10.0% in the 2nd quarter. Brighton Jones LLC now owns 3,742 shares of the medical research company's stock valued at $346,000 after acquiring an additional 339 shares during the last quarter. Ieq Capital LLC raised its position in shares of Edwards Lifesciences by 7.8% during the 2nd quarter. Ieq Capital LLC now owns 62,480 shares of the medical research company's stock valued at $5,771,000 after acquiring an additional 4,528 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in Edwards Lifesciences by 29.8% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 13,295 shares of the medical research company's stock worth $1,228,000 after purchasing an additional 3,049 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.
EW has been the subject of several recent research reports. Royal Bank of Canada boosted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research note on Thursday, December 5th. Truist Financial reiterated a "hold" rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 28th. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Finally, Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $78.48.
Get Our Latest Analysis on Edwards Lifesciences
In related news, VP Daniel J. Lippis sold 2,500 shares of the business's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,000 shares of company stock worth $2,195,180. Insiders own 1.27% of the company's stock.
NYSE:EW traded down $0.09 during trading hours on Friday, hitting $69.77. 5,031,232 shares of the company's stock traded hands, compared to its average volume of 4,364,863. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market cap of $41.15 billion, a P/E ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock's fifty day moving average price is $72.06 and its two-hundred day moving average price is $71.45.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the business posted $0.59 earnings per share. Edwards Lifesciences's revenue for the quarter was up 8.9% compared to the same quarter last year. On average, research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.